IMPLANET01.06.17
IMPLANET, a developer of vertebral and knee-surgery implants, announced that the European Patent Office has granted the company a European patent for its JAZZ implant’s universal tensioning system.
This latest European patent concerns the JAZZ implant’s tensioning system, which is the principal element of its instrumentation. It follows the patent granted in August 2016 by the U.S. Patent and Trademark Office, and completes a portfolio of intellectual property protecting Implanet’s technology in its priority markets.
Régis Le Couedic, Implanet’s research and development director, said: “The intellectual protection of the instrumentation used to insert JAZZ implants represents a strategic issue in itself for its adoption by the most-demanding spine surgeons. The decision to use an implant greatly depends on the quality and performance of the associated instrumentation. It is the combined use of the JAZZ implant and instruments that enables the surgeon to obtain optimal clinical results for the patient.”
“Obtaining this latest patent represents a key new milestone in value creation for the company," added CEO Ludovic Lastennet. "It is yet another hurdle for potential competitors hoping for market access, notably following the patent recently granted in the United States for this same instrumentation. We have compiled a comprehensive intellectual property portfolio with regard to both the components of our technology and the markets that place a strong emphasis on intellectual property rights on which we operate.”
Founded in 2007, IMPLANET manufactures orthopedic implants. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the U.S. Food and Drug Administration and the CE mark. IMPLANET employs 48 staff and recorded 2015 sales of 6.7 million euros. Based near Bordeaux in France, IMPLANET established a U.S. subsidiary in Boston, Mass., in 2013.
This latest European patent concerns the JAZZ implant’s tensioning system, which is the principal element of its instrumentation. It follows the patent granted in August 2016 by the U.S. Patent and Trademark Office, and completes a portfolio of intellectual property protecting Implanet’s technology in its priority markets.
Régis Le Couedic, Implanet’s research and development director, said: “The intellectual protection of the instrumentation used to insert JAZZ implants represents a strategic issue in itself for its adoption by the most-demanding spine surgeons. The decision to use an implant greatly depends on the quality and performance of the associated instrumentation. It is the combined use of the JAZZ implant and instruments that enables the surgeon to obtain optimal clinical results for the patient.”
“Obtaining this latest patent represents a key new milestone in value creation for the company," added CEO Ludovic Lastennet. "It is yet another hurdle for potential competitors hoping for market access, notably following the patent recently granted in the United States for this same instrumentation. We have compiled a comprehensive intellectual property portfolio with regard to both the components of our technology and the markets that place a strong emphasis on intellectual property rights on which we operate.”
Founded in 2007, IMPLANET manufactures orthopedic implants. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the U.S. Food and Drug Administration and the CE mark. IMPLANET employs 48 staff and recorded 2015 sales of 6.7 million euros. Based near Bordeaux in France, IMPLANET established a U.S. subsidiary in Boston, Mass., in 2013.